Cytokinetics Files 10-Q Amidst Public Offering and Loan Amendments

TL;DR

Cytokinetics 10-Q out: Public offering done, loan docs updated. Keep an eye on R&D.

AI Summary

Cytokinetics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and ongoing research and development activities. Key events include a public offering on May 28, 2024, and a loan agreement amendment on May 22, 2024.

Why It Matters

This filing provides investors with an update on Cytokinetics' financial health and strategic moves, including capital raising and debt management, which are crucial for its drug development pipeline.

Risk Assessment

Risk Level: medium — The company operates in the highly regulated and competitive pharmaceutical industry, with significant R&D expenses and reliance on successful drug development.

Key Players & Entities

• CYTOKINETICS INC (company) — Filer
• 20240630 (date) — Reporting Period End Date
• 20240809 (date) — Filing Date
• 350 OYSTER POINT BOULEVARD (address) — Business and Mail Address
• SOUTH SAN FRANCISCO (location) — City
• CA (location) — State
• 94080 (zip_code) — Zip Code
• 2024-05-22 (date) — Loan Agreement Amendment Date
• 2024-05-28 (date) — Public Offering Date

FAQ

Key Financial Figures

• $0.001 — : Title of each class Common Stock, $0.001 par value Trading symbol CYTK Nam

Filing Documents

• cytk-20240630.htm (10-Q) — 2450KB
• cytk-ex10_1.htm (EX-10.1) — 35KB
• cytk-ex10_3.htm (EX-10.3) — 183KB
• cytk-ex10_4.htm (EX-10.4) — 85KB
• cytk-ex10_5.htm (EX-10.5) — 483KB
• cytk-ex10_6.htm (EX-10.6) — 496KB
• cytk-ex10_7.htm (EX-10.7) — 154KB
• cytk-ex31_1.htm (EX-31.1) — 15KB
• cytk-ex31_2.htm (EX-31.2) — 15KB
• cytk-ex32_1.htm (EX-32.1) — 8KB
• img196648343_0.jpg (GRAPHIC) — 2KB
• 0000950170-24-094743.txt ( ) — 10753KB
• cytk-20240630.xsd (EX-101.SCH) — 1460KB
• cytk-20240630_htm.xml (XML) — 1323KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 7

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 7 Condensed Consolidated Balance Sheets 7 Condensed Consolidated Statements of Operations and Comprehensive Loss 8 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 9 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 25

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 46

Controls and Procedures

Item 4. Controls and Procedures 46

OTHER INFORMATION

PART II. OTHER INFORMATION 47

Legal Proceedings

Item 1. Legal Proceedings 47

Risk Factors

Item 1A. Risk Factors 47

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 77

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 77

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 77

Other Information

Item 5. Other Information 77

Exhibits

Item 6. Exhibits 78

SIGNATURES

SIGNATURES 80 2 Table of Contents Glossary of Terms Unless the context requires otherwise, references to "Cytokinetics," "the Company," "we," "us" or "our" in this Quarterly Report on Form 10-Q refer to Cytokinetics, Incorporated and its subsidiaries. References to "Notes" in this Form 10-Q are to the Notes to the Condensed Consolidated Financial Statements in this Form 10-Q. We also have used other specific terms in this Form 10-Q, most of which are explained or defined below: Term/Abbreviation Definition 2004 Plan Cytokinetics' Amended and Restated 2004 Equity Incentive Plan 2020 RTW Transactions The transactions contemplated by the RTW Royalty Purchase Agreement, Ji Xing Aficamten License Agreement and the Common Stock Purchase Agreements, dated July 14, 2020, by and between Cytokinetics and the RTW Investors 2021 RTW Transactions The transactions contemplated by the Ji Xing OM License Agreement and the Common Stock Purchase Agreements, dated December 20, 2021 by and between Cytokinetics and the RTW Investors 2022 RPI Transactions The transactions contemplated by the RP Multi Tranche Loan Agreement and the RP Aficamten RPA 2024 RPI Transactions The transactions contemplated by the 2024 RP OM Loan Agreement, the RP CK-586 RPA, the RP Stock Purchase Agreement, the 2022 RP Multi Tranche Loan Agreement Amendment and the RP Aficamten RPA Amendment 2026 Notes Cytokinetics' 4% convertible senior notes due 2026 2027 Indenture Indenture Agreement, dated July 6, 2022, between Cytokinetics and U.S. Bank Trust Company, as trustee 2027 Notes Cytokinetics' 3.50% convertible senior notes due 2027 ACA Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act ACACIA-HCM Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM ACC American College of Cardiology AHA American Heart Association ALS amyotrophic lateral sclerosis (a

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

FINANCI AL STATEMENTS

ITEM 1. FINANCI AL STATEMENTS CYTOKINETICS, INCORPORATED CONDENSED CONSOLIDAT ED BALANCE SHEETS (In thousands) (Unaudited) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 190,142 $ 113,024 Short-term investments 866,633 501,800 Accounts receivable — 1,283 Prepaid expenses and other current assets 11,035 11,944 Total current assets 1,067,810 628,051 Long-term investments 305,361 40,534 Property and equipment, net 65,689 68,748 Operating lease right-of-use assets 77,249 78,987 Other assets 7,679 7,996 Total assets $ 1,523,788 $ 824,316 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 9,470 $ 21,507 Accrued liabilities 39,813 42,641 Short-term operating lease liabilities 18,507 17,891 Current portion of long-term debt 11,520 10,080 Derivative liabilities measured at fair value 13,200 — Other current liabilities 10,267 10,559 Total current liabilities 102,777 102,678 Term loans, net 92,831 58,384 Convertible notes, net 550,600 548,989 Liabilities related to revenue participation right purchase agreements, net 435,112 379,975 Long-term operating lease liabilities 116,718 120,427 Liabilities related to RPI Transactions measured at fair value 117,200 — Other non-current liabilities — 186 Total liabilities 1,415,238 1,210,639 Commitments and contingencies Stockholders' equity (deficit): Preferred stock — — Common stock 117 102 Additional paid-in capital 2,500,654 1,725,823 Accumulated other comprehensive loss ( 1,022 ) ( 10 ) Accumulated deficit ( 2,391,199 ) ( 2,112,238 ) Total stockholders' equity (deficit) 108,550 ( 386,323 ) Total liabilities and stockholders' equity (deficit) $ 1,523,788 $ 824,316 The accompanying notes are an integral part of these condensed consol

View Full Filing

View this 10-Q filing on SEC EDGAR